180 Wealth Advisors LLC Grows Position in GRAIL, Inc. $GRAL

180 Wealth Advisors LLC grew its position in GRAIL, Inc. (NASDAQ:GRAL) by 10.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 127,347 shares of the company’s stock after acquiring an additional 12,300 shares during the quarter. GRAIL accounts for 0.7% of 180 Wealth Advisors LLC’s portfolio, making the stock its 26th biggest holding. 180 Wealth Advisors LLC owned approximately 0.30% of GRAIL worth $6,581,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GRAL. N.E.W. Advisory Services LLC purchased a new position in shares of GRAIL in the fourth quarter valued at $26,000. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL during the fourth quarter valued at $28,000. Elyxium Wealth LLC bought a new position in GRAIL during the fourth quarter valued at $31,000. Comerica Bank lifted its position in GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after purchasing an additional 173 shares during the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after buying an additional 472 shares in the last quarter.

Wall Street Analysts Forecast Growth

GRAL has been the topic of several recent research reports. Wolfe Research started coverage on shares of GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Mizuho initiated coverage on GRAIL in a research report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price target for the company. Guggenheim reduced their price objective on GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. TD Cowen upped their price objective on GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GRAIL has an average rating of “Hold” and an average target price of $67.00.

GRAIL Trading Down 5.0%

Shares of NASDAQ GRAL traded down $3.79 during midday trading on Friday, hitting $72.00. The company’s stock had a trading volume of 509,860 shares, compared to its average volume of 564,771. The business’s 50 day moving average is $64.29 and its two-hundred day moving average is $70.02. GRAIL, Inc. has a 12-month low of $29.95 and a 12-month high of $118.84. The firm has a market cap of $3.09 billion, a P/E ratio of -6.94 and a beta of 3.22.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. The company had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. On average, analysts predict that GRAIL, Inc. will post -10.91 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares of the company’s stock, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.83% of the company’s stock.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Several law firms, including Rosen, Berger Montague, Schall, Faruqi & Faruqi, Levi & Korsinsky, and others, are reminding investors about the ongoing class action and the August 4, 2026 lead plaintiff deadline, keeping the legal issue in focus. Article Title
• Neutral Sentiment: Robbins LLP and other firms are urging stockholders who bought shares during the alleged class period to contact them for information about joining the lawsuit, suggesting the case is still actively being marketed to affected investors. Article Title
• Negative Sentiment: The core negative takeaway is that the lawsuit centers on the February 20, 2026 trial update, which reportedly erased more than $2.2 billion in market value and is now being framed as securities fraud, a headline that can weigh on investor sentiment. Article Title

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.